Systematic prioritization of druggable mutations in ~5000 genomes across 16 cancer types using a structural genomics-based approachS

Molecular and Cellular Proteomics

Volumn 15, Issue 2, 2016, Pages 642-656

  Zhao, Junfei ^a   Cheng, Feixiong ^a   Wang, Yuanyuan ^a   Arteaga, Carlos L ^a,b   Zhao, Zhongming ^a,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAYES THEOREM; BIOLOGY; GENE EXPRESSION REGULATION; GENETICS; GENOMICS; HUMAN; HUMAN GENOME; MISSENSE MUTATION; NEOPLASM; PATHOLOGY;

BAYES THEOREM; COMPUTATIONAL BIOLOGY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; GENOMICS; HUMANS; MUTATION, MISSENSE; NEOPLASMS;

EID: 84957916292     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M115.053199     Document Type: Article

References (75)

1. Hudson, T. J., Anderson, W., Artez, A., Barker, A. D., Bell, C., Bernabe, R. R., Bhan, M. K., Calvo, F., Eerola, I., Gerhard, D. S., Guttmacher, A., Guyer, M., Hemsley, F. M., Jennings, J. L., Kerr, D., Klatt, P., Kolar, P., Kusada, J., Lane, D. P., Laplace, F., Youyong, L., Nettekoven, G., Ozen-berger, B., Peterson, J., Rao, T. S., Remacle, J., Schafer, A. J., Shibata, T., Stratton, M. R., Vockley, J. G., Watanabe, K., Yang, H., Yuen, M. M., Knoppers, B. M., Bobrow, M., Cambon-Thomsen, A., Dressler, L. G., Dyke, S. O., Joly, Y., Kato, K., Kennedy, K. L., Nicolas, P., Parker, M. J., Rial-Sebbag, E., Romeo-Casabona, C. M., Shaw, K. M., Wallace, S., Wiesner, G. L., Zeps, N., Lichter, P., Biankin, A. V., Chabannon, C., Chin, L., Clement, B., de Alava, E., Degos, F., Ferguson, M. L., Geary, P., Hayes, D. N., Johns, A. L., Kasprzyk, A., Nakagawa, H., Penny, R., Piris, M. A., Sarin, R., Scarpa, A., van de Vijver, M., Futreal, P. A., Aburatani, H., Bayes, M., Botwell, D. D., Campbell, P. J., Estivill, X., Grimmond, S. M., Gut, I., Hirst, M., Lopez-Otin, C., Majumder, P., Marra, M., McPherson, J. D., Ning, Z., Puente, X. S., Ruan, Y., Stunnenberg, H. G., Swerdlow, H., Velculescu, V. E., Wilson, R. K., Xue, H. H., Yang, L., Spellman, P. T., Bader, G. D., Boutros, P. C., Flicek, P., Getz, G., Guigo, R., Guo, G., Haussler, D., Heath, S., Hubbard, T. J., Jiang, T., Jones, S. M., Li, Q., Lopez-Bigas, N., Luo, R., Muthuswamy, L., Ouellette, B. F., Pearson, J. V., Quesada, V., Raphael, B. J., Sander, C., Speed, T. P., Stein, L. D., Stuart, J. M., Teague, J. W., Totoki, Y., Tsunoda, T., Valencia, A., Wheeler, D. A., Wu, H., Zhao, S., Zhou, G., Lathrop, M., Thomas, G., Yoshida, T., Axton, M., Gunter, C., Miller, L. J., Zhang, J., Haider, S. A., Wang, J., Yung, C. K., Cros, A., Liang, Y., Gnaneshan, S., Guberman, J., Hsu, J., Chalmers, D. R., Hasel, K. W., Kaan, T. S., Lowrance, W. W., Masui, T., Rodriguez, L. L., Vergely, C., Bowtell, D. D., Cloonan, N., deFazio, A., Eshleman, J. R., Etemadmoghadam, D., Gardiner, B. B., Kench, J. G., Sutherland, R. L., Tempero, M. A., Waddell, N. J., Wilson, P. J., Gallinger, S., Tsao, M. S., Shaw, P. A., Petersen, G. M., Mukhopadhyay, D., DePinho, R. A., Thayer, S., Shazand, K., Beck, T., Sam, M., Timms, L., Ballin, V., Lu, Y., Ji, J., Zhang, X., Chen, F., Hu, X., Yang, Q., Tian, G., Zhang, L., Xing, X., Li, X., Zhu, Z., Yu, Y., Yu, J., Tost, J., Brennan, P., Holcatova, I., Zaridze, D., Brazma, A., Egevard, L., Prokhortchouk, E., Banks, R. E., Uhlen, M., Viksna, J., Ponten, F., Skryabin, K., Birney, E., Borg, A., Borresen-Dale, A. L., Caldas, C., Foekens, J. A., Martin, S., Reis-Filho, J. S., Richardson, A. L., Sotiriou, C., Thoms, G., vant Veer, L., Birnbaum, D., Blanche, H., Boucher, P., Boyault, S., Masson-Jacquemier, J. D., Pauporte, I., Pivot, X., Vincent-Salomon, A., Tabone, E., Theillet, C., Treilleux, I., Bioulac-Sage, P., Decaens, T., Franco, D., Gut, M., Samuel, D., Zucman-Rossi, J., Eils, R., Brors, B., Korbel, J. O., Korshunov, A., Landgraf, P., Lehrach, H., Pfister, S., Radlwimmer, B., Reifenberger, G., Taylor, M. D., von Kalle, C., Majumder, P. P., Pederzoli, P., Lawlor, R. A., Delledonne, M., Bardelli, A., Gress, T., Klimstra, D., Zamboni, G., Nakamura, Y., Miyano, S., Fujimoto, A., Campo, E., de Sanjose, S., Montserrat, E., Gonzalez-Diaz, M., Jares, P., Himmelbauer, H., Bea, S., Aparicio, S., Easton, D. F., Collins, F. S., Compton, C. C., Lander, E. S., Burke, W., Green, A. R., Hamilton, S. R., Kallioniemi, O. P., Ley, T. J., Liu, E. T., and Wainwright, B. J. (2010) International network of cancer genome projects. Nature 464, 993-998
2. Chin, L., Andersen, J. N., and Futreal, P. A. (2011) Cancer genomics: from discovery science to personalized medicine. Nat. Med. 17, 297-303
3. Takebe, N., McShane, L., and Conley, B. (2015) Biomarkers: Exceptional responders-discovering predictive biomarkers. Nat. Rev. Clin. Oncol. 12, 132-134
4. Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., Jr., and Kinzler, K. W. (2013) Cancer genome landscapes. Science 339, 1546-1558
5. Tomasetti, C., Marchionni, L., Nowak, M. A., Parmigiani, G., and Vogelstein, B. (2015) Only three driver gene mutations are required for the development of lung and colorectal cancers. Proc. Natl. Acad. Sci. U.S.A. 112, 118-123
6. Raphael, B. J., Dobson, J. R., Oesper, L., and Vandin, F. (2014) Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. Genome Med. 6, 5
7. Jones, S., Anagnostou, V., Lytle, K., Parpart-Li, S., Nesselbush, M., Riley, D. R., Shukla, M., Chesnick, B., Kadan, M., Papp, E., Galens, K. G., Murphy, D., Zhang, T., Kann, L., Sausen, M., Angiuoli, S. V., Diaz, L. A., Jr., and Velculescu, V. E. (2015) Personalized genomic analyses for cancer mutation discovery and interpretation. Sci. Transl. Med. 7, 283ra253
8. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., and Bourne, P. E. (2000) The Protein Data Bank. Nucleic Acids Res. 28, 235-242
9. Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M. J., Sellers, W. R., Johnson, B. E., and Meyerson, M. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500
10. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., Louis, D. N., Christiani, D. C., Settleman, J., and Haber, D. A. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139
11. Chandonia, J. M., and Brenner, S. E. (2006) The impact of structural genomics: expectations and outcomes. Science 311, 347-351
12. Vuong, H., Cheng, F., Lin, C. C., and Zhao, Z. (2014) Functional consequences of somatic mutations in cancer using protein pocket-based prioritization approach. Genome Med. 6, 81
13. Cheng, F., Zhao, J., and Zhao, Z. (2015) Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes. Brief. Bioinform. bbv068
14. Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., Kiezun, A., Hammerman, P. S., McKenna, A., Drier, Y., Zou, L., Ramos, A. H., Pugh, T. J., Stransky, N., Helman, E., Kim, J., Sougnez, C., Ambrogio, L., Nickerson, E., Shefler, E., Cortes, M. L., Auclair, D., Saksena, G., Voet, D., Noble, M., DiCara, D., Lin, P., Lichtenstein, L., Heiman, D. I., Fennell, T., Imielinski, M., Hernandez, B., Hodis, E., Baca, S., Dulak, A. M., Lohr, J., Landau, D. A., Wu, C. J., Melendez-Zajgla, J., Hidalgo-Miranda, A., Koren, A., McCarroll, S. A., Mora, J., Lee, R. S., Crompton, B., Onofrio, R., Parkin, M., Winckler, W., Ardlie, K., Gabriel, S. B., Roberts, C. W., Biegel, J. A., Stegmaier, K., Bass, A. J., Garraway, L. A., Meyerson, M., Golub, T. R., Gordenin, D. A., Sunyaev, S., Lander, E. S., and Getz, G. (2013) Mutational heterogeneity in cancer and the search for new cancer-Associated genes. Nature 499, 214-218
15. Hua, X., Xu, H., Yang, Y., Zhu, J., Liu, P., and Lu, Y. (2013) DrGaP: A powerful tool for identifying driver genes and pathways in cancer sequencing studies. Am. J. Hum. Genet. 93, 439-451
16. Ng, P. C., and Henikoff, S. (2003) SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res. 31, 3812-3814
17. Reva, B., Antipin, Y., and Sander, C. (2011) Predicting the functional impact of protein mutations: Application to cancer genomics. Nucleic Acids Res. 39, e118
18. Tamborero, D., Gonzalez-Perez, A., and Lopez-Bigas, N. (2013) Oncodrive-CLUST: exploiting the positional clustering of somatic mutations to identify cancer genes. Bioinformatics 29, 2238-2244
19. Porta-Pardo, E., and Godzik, A. (2014) e-Driver: A novel method to identify protein regions driving cancer. Bioinformatics 30, 3109-3114
20. Jia, P., Wang, Q., Chen, Q., Hutchinson, K. E., Pao, W., and Zhao, Z. (2014) MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysis. Genome Biol. 15, 489
21. Cheng, F., Jia, P., Wang, Q., Lin, C. C., Li, W. H., and Zhao, Z. (2014) Studying tumorigenesis through network evolution and somatic mutational perturbations in the cancer interactome. Mol. Biol. Evol. 31, 2156-2169
22. Jia, P., and Zhao, Z. (2014) VarWalker: personalized mutation network analysis of putative cancer genes from next-generation sequencing data. PLoS Comput. Biol. 10, e1003460
23. Leiserson, M. D., Vandin, F., Wu, H. T., Dobson, J. R., Eldridge, J. V., Thomas, J. L., Papoutsaki, A., Kim, Y., Niu, B., McLellan, M., Lawrence, M. S., Gonzalez-Perez, A., Tamborero, D., Cheng, Y., Ryslik, G. A., Lopez-Bigas, N., Getz, G., Ding, L., and Raphael, B. J. (2015) Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat. Genet. 47, 106-114
24. Rubio-Perez, C., Tamborero, D., Schroeder, M. P., Antolin, A. A., Deu-Pons, J., Perez-Llamas, C., Mestres, J., Gonzalez-Perez, A., and Lopez-Bigas, N. (2015) In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer Cell 27, 382-396
25. Davoli, T., Xu, A. W., Mengwasser, K. E., Sack, L. M., Yoon, J. C., Park, P. J., and Elledge, S. J. (2013) Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell 155, 948-962
26. Wang, K., Li, M., and Hakonarson, H. (2010) ANNOVAR: functional annotation of genetic variants from high-Throughput sequencing data. Nucleic Acids Res. 38, e164-e164
27. Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., and Sunyaev, S. R. (2010) A method and server for predicting damaging missense mutations. Nat. Methods 7, 248-249
28. Zhu, Y., Qiu, P., and Ji, Y. (2014) TCGA-Assembler: open-source software for retrieving and processing TCGA data. Nat. Methods 11, 599-600
29. Yang, J., Roy, A., and Zhang, Y. (2013) BioLiP: A semi-manually curated database for biologically relevant ligand-protein interactions. Nucleic Acids Res. 41, D1096-D1103
30. Hochberg, Y., and Benjamini, Y. (1990) More powerful procedures for multiple significance testing. Statistics Med. 9, 811-818
31. Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., Teague, J. W., Campbell, P. J., Stratton, M. R., and Futreal, P. A. (2011) COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945-D950
32. Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., and Stratton, M. R. (2004) A census of human cancer genes. Nat. Rev. Cancer 4, 177-183
33. Cheng, F., Liu, C., Lin, C. C., Zhao, J., Jia, P., Li, W. H., and Zhao, Z. (2015) A Gene Gravity Model for the Evolution of Cancer Genomes: A Study of 3, 000 Cancer Genomes across 9 Cancer Types. PLoS Comput. Biol. 11, e1004497
34. Knox, C., Law, V., Jewison, T., Liu, P., Ly, S., Frolkis, A., Pon, A., Banco, K., Mak, C., Neveu, V., Djoumbou, Y., Eisner, R., Guo, A. C., and Wishart, D. S. (2011) DrugBank 3.0: A comprehensive resource for omics research on drugs. Nucleic Acids Res. 39, D1035-D1041
35. Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., and Overington, J. P. (2012) ChEMBL: A large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100-D1107
36. Liu, T., Lin, Y., Wen, X., Jorissen, R. N., and Gilson, M. K. (2007) BindingDB: A web-Accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res. 35, D198-D201
37. Cheng, F., Zhou, Y., Li, W., Liu, G., and Tang, Y. (2012) Prediction of chemical-protein interactions network with weighted network-based inference method. PLoS ONE 7, e41064
38. Cheng, F., Liu, C., Jiang, J., Lu, W., Li, W., Liu, G., Zhou, W., Huang, J., and Tang, Y. (2012) Prediction of drug-Target interactions and drug repositioning via network-based inference. PLoS Comput. Biol. 8, e1002503
39. Cheng, F., Li, W., Wu, Z., Wang, X., Zhang, C., Li, J., Liu, G., and Tang, Y. (2013) Prediction of polypharmacological profiles of drugs by the integration of chemical, side effect, and therapeutic space. J. Chem. Inf. Model 53, 753-762
40. Corrdinators, N. R. (2013) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 41, D8-D20
41. Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., Hudis, C., Chen, D., Taran, T., Hortobagyi, G., Greene, G., Berger, M., Baselga, J., and Chandarlapaty, S. (2013) ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 45, 1439-1445
42. Nettles, K. W., Bruning, J. B., Gil, G., Nowak, J., Sharma, S. K., Hahm, J. B., Kulp, K., Hochberg, R. B., Zhou, H., Katzenellenbogen, J. A., Katzenellenbogen, B. S., Kim, Y., Joachmiak, A., and Greene, G. L. (2008) NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses. Nat. Chem. Biol. 4, 241-247
43. Sanner, M. F. (1999) Python: A programming language for software integration and development. J. Mol. Graph. Model 17, 57-61
44. Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., and Ferrin, T. E. (2004) UCSF Chimera-A visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612
45. Trott, O., and Olson, A. J. (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455-461
46. Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., and Ideker, T. (2003) Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498-2504
47. Cancer Genome Atlas, N. (2012) Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70
48. Arteaga, C. L., and Engelman, J. A. (2014) ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 25, 282-303
49. Cancer Genome Atlas Research, N. (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543-550
50. Delassus, G. S., Cho, H., Park, J., and Eliceiri, G. L. (2008) New pathway links from cancer-progression determinants to gene expression of matrix metalloproteinases in breast cancer cells. J. Cell. Physiol. 217, 739-744
51. Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J. P., Nickerson, E., Auclair, D., Li, L., Place, C., Dicara, D., Ramos, A. H., Lawrence, M. S., Cibulskis, K., Sivachenko, A., Voet, D., Saksena, G., Stransky, N., Onofrio, R. C., Winckler, W., Ardlie, K., Wagle, N., Wargo, J., Chong, K., Morton, D. L., Stemke-Hale, K., Chen, G., Noble, M., Meyerson, M., Ladbury, J. E., Davies, M. A., Gershenwald, J. E., Wagner, S. N., Hoon, D. S., Schadendorf, D., Lander, E. S., Gabriel, S. B., Getz, G., Garraway, L. A., and Chin, L. (2012) A landscape of driver mutations in melanoma. Cell 150, 251-263
52. Krauthammer, M., Kong, Y., Ha, B. H., Evans, P., Bacchiocchi, A., Mc-Cusker, J. P., Cheng, E., Davis, M. J., Goh, G., Choi, M., Ariyan, S., Narayan, D., Dutton-Regester, K., Capatana, A., Holman, E. C., Bosenberg, M., Sznol, M., Kluger, H. M., Brash, D. E., Stern, D. F., Materin, M. A., Lo, R. S., Mane, S., Ma, S., Kidd, K. K., Hayward, N. K., Lifton, R. P., Schlessinger, J., Boggon, T. J., and Halaban, R. (2012) Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006-1014
53. Goswami, M., Hensel, N., Smith, B. D., Prince, G. T., Qin, L., Levitsky, H. I., Strickland, S. A., Jagasia, M., Savani, B. N., Fraser, J. W., Sadrzadeh, H., Rajkhowa, T., Ito, S., Jain, N. A., Battiwalla, M., Fathi, A. T., Levis, M. J., Barrett, A. J., and Hourigan, C. S. (2014) Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues. Leukemia 28, 1167-1170
54. Weickert, M. O., Loeffelholz, C. V., Roden, M., Chandramouli, V., Brehm, A., Nowotny, P., Osterhoff, M. A., Isken, F., Spranger, J., Landau, B. R., Pfeiffer, A. F., and Mohlig, M. (2007) A Thr94Ala mutation in human liver fatty acid-binding protein contributes to reduced hepatic glycogenolysis and blunted elevation of plasma glucose levels in lipid-exposed subjects. Am. J. Physiol. Endocrinol Metab. 293, E1078-E1084
55. Tolle, A., Suhail, S., Jung, M., Jung, K., and Stephan, C. (2011) Fatty acid binding proteins (FABPs) in prostate, bladder and kidney cancer cell lines and the use of IL-FABP as survival predictor in patients with renal cell carcinoma. BMC Cancer 11, 302
56. Kim, P., Cheng, F., Zhao, J., and Zhao, Z. (2015) ccmGDB: A database for cancer cell metabolism genes. Nucleic Acids Res. gkv1128
57. Yeh, H. H., Ogawa, K., Balatoni, J., Mukhapadhyay, U., Pal, A., Gonzalez-Lepera, C., Shavrin, A., Soghomonyan, S., Flores, L., 2nd, Young, D., Volgin, A. Y., Najjar, A. M., Krasnykh, V., Tong, W., Alauddin, M. M., and Gelovani, J. G. (2011) Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT. Proc. Natl. Acad. Sci. U.S.A. 108, 1603-1608
58. Theurillat, J. P., Udeshi, N. D., Errington, W. J., Svinkina, T., Baca, S. C., Pop, M., Wild, P. J., Blattner, M., Groner, A. C., Rubin, M. A., Moch, H., Prive, G. G., Carr, S. A., and Garraway, L. A. (2014) Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science 346, 85-89
59. Li, S., Shen, D., Shao, J., Crowder, R., Liu, W., Prat, A., He, X., Liu, S., Hoog, J., Lu, C., Ding, L., Griffith, O. L., Miller, C., Larson, D., Fulton, R. S., Harrison, M., Mooney, T., McMichael, J. F., Luo, J., Tao, Y., Goncalves, R., Schlosberg, C., Hiken, J. F., Saied, L., Sanchez, C., Giuntoli, T., Bumb, C., Cooper, C., Kitchens, R. T., Lin, A., Phommaly, C., Davies, S. R., Zhang, J., Kavuri, M. S., McEachern, D., Dong, Y. Y., Ma, C., Pluard, T., Naughton, M., Bose, R., Suresh, R., McDowell, R., Michel, L., Aft, R., Gillanders, W., DeSchryver, K., Wilson, R. K., Wang, S., Mills, G. B., Gonzalez-Angulo, A., Edwards, J. R., Maher, C., Perou, C. M., Mardis, E. R., and Ellis, M. J. (2013) Endocrine-Therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 4, 1116-1130
60. Robinson, D. R., Wu, Y. M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., Gursky, A., Siddiqui, J., Tomlins, S. A., Roychowdhury, S., Pienta, K. J., Kim, S. Y., Roberts, J. S., Rae, J. M., Van Poznak, C. H., Hayes, D. F., Chugh, R., Kunju, L. P., Talpaz, M., Schott, A. F., and Chinnaiyan, A. M. (2013) Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 45, 1446-1451
61. Lu, N. Z., Wardell, S. E., Burnstein, K. L., Defranco, D., Fuller, P. J., Giguere, V., Hochberg, R. B., McKay, L., Renoir, J. M., Weigel, N. L., Wilson, E. M., McDonnell, D. P., and Cidlowski, J. A. (2006) International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol. Rev. 58, 782-797
62. Skor, M. N., Wonder, E. L., Kocherginsky, M., Goyal, A., Hall, B. A., Cai, Y., and Conzen, S. D. (2013) Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin. Cancer Res. 19, 6163-6172
63. Lauriola, M., Enuka, Y., Zeisel, A., DUva, G., Roth, L., Sharon-Sevilla, M., Lindzen, M., Sharma, K., Nevo, N., Feldman, M., Carvalho, S., Cohen-Dvashi, H., Kedmi, M., Ben-Chetrit, N., Chen, A., Solmi, R., Wiemann, S., Schmitt, F., Domany, E., and Yarden, Y. (2014) Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment. Nat. Commun. 5, 5073
64. Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., and Shokat, K. M. (2013) K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548-551
65. Hunter, J. C., Gurbani, D., Ficarro, S. B., Carrasco, M. A., Lim, S. M., Choi, H. G., Xie, T., Marto, J. A., Chen, Z., Gray, N. S., and Westover, K. D. (2014) In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C. Proc. Natl. Acad. Sci. U.S.A. 111, 8895-8900
66. Cancer Genome Atlas Research, N. (2014) Integrated genomic characterization of papillary thyroid carcinoma. Cell 159, 676-690
67. Reddy, A. P., Chen, J. Y., Zacharewski, T., Gronemeyer, H., Voorhees, J. J., and Fisher, G. J. (1992) Characterization and purification of human retinoic acid receptor-gamma 1 overexpressed in the baculovirus-insect cell system. Biochem. J. 287 (Pt 3), 833-840
68. Parrella, E., Gianni, M., Fratelli, M., Barzago, M. M., Raska, I., Jr., Diomede, L., Kurosaki, M., Pisano, C., Carminati, P., Merlini, L., Dallavalle, S., Tavecchio, M., Rochette-Egly, C., Terao, M., and Garattini, E. (2006) Antitumor activity of the retinoid-related molecules (E)-3-(4-hydroxy-3-Adamantylbiphenyl-4-yl)acrylic acid (ST1926) and 6-[3-(1-Adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) in F9 teratocarcinoma: Role of retinoic acid receptor gamma and retinoid-independent pathways. Mol. Pharmacol. 70, 909-924
69. Kim, M. J., Ciletti, N., Michel, S., Reichert, U., and Rosenfield, R. L. (2000) The role of specific retinoid receptors in sebocyte growth and differentiation in culture. J. Invest. Dermatol. 114, 349-353
70. Laaksovirta, S., Rajala, P., Nurmi, M., Tammela, T. L., and Laato, M. (1999) The cytostatic effect of 9-cis-retinoic acid, tretinoin, and isotretinoin on three different human bladder cancer cell lines in vitro. Urol. Res. 27, 17-22
71. Lawrence, J. A., Adamson, P. C., Caruso, R., Chow, C., Kleiner, D., Murphy, R. F., Venzon, D. J., Shovlin, M., Noone, M., Merino, M., Cowan, K. H., Kaiser, M., OShaughnessy, J., and Zujewski, J. (2001) Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: Toxicity, pharmacokinetic, and biomarker evaluations. J. Clin. Oncol. 19, 2754-2763
72. Kamburov, A., Lawrence, M. S., Polak, P., Leshchiner, I., Lage, K., Golub, T. R., Lander, E. S., and Getz, G. (2015) Comprehensive assessment of cancer missense mutation clustering in protein structures. Proc. Natl. Acad. Sci. U.S.A.
73. Khoo, K. H., Verma, C. S., and Lane, D. P. (2014) Drugging the p53 pathway: understanding the route to clinical efficacy. Nat. Rev. Drug Discov. 13, 217-236
74. Cheng, F., Jia, P., Wang, Q., and Zhao, Z. (2014) Quantitative network mapping of the human kinome interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer therapy. Oncotarget 5, 3697-3710
75. Carreira, S., Romanel, A., Goodall, J., Grist, E., Ferraldeschi, R., Miranda, S., Prandi, D., Lorente, D., Frenel, J.-S., and Pezaro, C. (2014) Tumor clone dynamics in lethal prostate cancer. Sci. Transl. Med. 6, 254ra125-254ra125